Black Diamond Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $102.3M
- Price
- $1.78
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.73%
- Volume
- 112.4K
About
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Quick stats
Shares outstanding57.5M
Computed float42.5M
Float / shares74.0%
Cash runway (months)37.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001701541
AI Summary
AI-generated1/9
minorneutralother
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Black Diamond Therapeutics announced that Chief Scientific Officer Elizabeth Buck, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York, and will host one-on-one investor meetings the same day.
The webcast goes live at 10:00-10:30am ET under Events and Presentations on the company's website, with a replay archived for 90 days.
The appearance comes as the clinical-stage oncology company advances silevertinib, a brain-penetrant fourth-generation EGFR inhibitor, in an ongoing Phase 2 trial in non-classical EGFRm NSCLC and a randomized Phase 2 trial in newly diagnosed EGFRvIII-positive GBM initiated in May 2026, with over 200 patients treated to date.